Your Shopping Cart
By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close
FDA Releases IDE Guidance on Neurological Device Trials
- By: Staff Editor
- Date: November 11, 2016
- Source: http://www.meddeviceonline.com/doc/fda-finalizes-ide-guidance-on-neurological-device-trials-0001
The US FDA has issued final guidance intended to assist FDA staff and those in the healthcare industry with submitting investigational device exemption (IDE) applications to conduct clinical trials for neurological medical devices.
The guidance applies to medical devices designed to target the cause or progression of neurological diseases, such as Alzheimer’s disease, Parkinson’s disease, or primary dystonia. The final guidance offers general study design considerations for clinical trials that investigate neurological devices using biological markers and clinical outcome assessments.
Investigational Plans
An IDE application should include the complete, or at least a summary, of the investigational plan, which also must contain a description of the device and its important components.
For each planned clinical study, the following should be provided:
- the proposed indications for use, which should include the target population;
- the study type (e.g., pivotal, expansion or feasibility trial);
- the design of the study, including objectives, any masking, randomization, and controls (e.g., best medical management, delayed time-to-treatment in the control arm in comparison to active treatment);
- the total time planned for subject follow-up;
- the number of subjects you plan to enroll (sample size);
- the number of investigational sites, both inside and outside the U.S.;
- the subject inclusion and exclusion criteria;
- primary safety and effectiveness endpoints described as specific objective clinical targets;
- a study plan detailing tests and testing methodologies one plan to test in the subjects;
- a schedule/time table of all clinical tests to be performed for pre- and post-¬ operative evaluation of the subjects.
- the participating investigators, if known.
Related Training:
Compliance Trainings
How FDA trains its investigators to review CAPA and what should you do to prepare
By - Jeff Kasoff
On Demand Access Anytime
By - Jeff Kasoff
On Demand Access Anytime
Excel Spreadsheets; Ensuring Data Integrity and 21 CFR Part 11 Compliance
By - David Nettleton
Live January 21, 2025
By - David Nettleton
Live January 21, 2025
Water System Investigation "How-To's" and Example Case Studies
By - T.C Soli
On Demand Access Anytime
By - T.C Soli
On Demand Access Anytime
Solutions for Addressing Fungal and Bacterial Spore Outbreaks in Pharmaceutical, Biotech, and Medical Device Operations
By - Jim Polarine
On Demand Access Anytime
By - Jim Polarine
On Demand Access Anytime
Compliance Standards
Best Sellers
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
By: Miles HutchinsonAdd to CartPrice: $249
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
San Francisco, CA | Aug 6-7, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 18-19, 2020
-
Los Angeles, CA | Aug 20-21, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 25-26, 2020
-
Virtual Seminar | Jun 10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | Jul 6-7, 2020
-
San Francisco, CA | Oct 22-23, 2020
-
Virtual Seminar | Jul 9-10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | June 3-4, 2020
-
Miami, FL | Jul 29-31, 2020
-
Virtual Seminar | Jun 17, 2020
-
Provider: ANSIAdd to CartPrice: $142
- Add to Cart
- Add to Cart
- Add to Cart
-
Provider: ANSIAdd to CartPrice: $120
-
Provider: ANSIAdd to CartPrice: $250
-
Provider: SEPTAdd to CartPrice: $299
- Add to Cart
-
Provider: Quality-Control-PlanAdd to CartPrice: $37
- Add to Cart
-
Provider: At-PQCAdd to CartPrice: $397
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
You Recently Viewed